Welcome to the international HTA database

Showing [23368 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Latanoprost/netarsudil (primary open-angle glaucoma and ocular hypertension) – Addendum to Commission A22-129]
2023	WorkSafeBC	Causal association between firefighting and hypersensitivity pneumonitis
2023	Agency for Care Effectiveness (ACE)	Aortic hybrid stent graft for treating complex aortic disease
2023	National Institute for Health and Care Excellence (NICE)	Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments. NICE technology appraisal guidance 930
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Risankizumab (Crohn disease) – Addendum to Commission A22-133]
2023	WorkSafeBC	Association between wearing orthosis and developing metatarsal stress fractures
2023	Agency for Care Effectiveness (ACE)	Thoracic and abdominal endovascular repair (T/EVAR) for the structural support of aortic aneurysm
2023	National Institute for Health and Care Excellence (NICE)	Zanubrutinib for treating chronic lymphocytic leukaemia. NICE technology appraisal guidance 931
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tixagevimab/cilgavimab (COVID-19) - benefit assessment according to § 35a Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Evidence report: V21-12H: Psychological consequences of abortion. Evidence report for the S3 guideline on abortion in the first trimester]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Zanubrutinib (chronic lymphocytic leukaemia) – Addendum to Commission A22-130]
2023	WorkSafeBC	Hemorrhoids and heavy lifting
2023	Agency for Care Effectiveness (ACE)	Sirolimus-coated percutaneous transluminal coronary angioplasty balloon catheters (SCBs) for patients with coronary artery disease (CAD)
2023	National Institute for Health and Care Excellence (NICE)	Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal). NICE technology appraisal guidance 932
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Relationship between volume of services and quality of treatment outcome for colorectal cancer surgery]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tixagevimab/cilgavimab (COVID-19) – Benefit assessment according to §35a Social Code Book V]
2023	WorkSafeBC	HEPA filters and nanomaterials
2023	National Institute for Health and Care Excellence (NICE)	Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal). NICE technology appraisal guidance 933
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Trastuzumab deruxtecan (breast cancer, after 1 prior therapy) - Addendum to Commission A22-80]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: evaluation and implementation of digital health solutions - a look at user participation]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Luspatercept (transfusion-dependent beta-thalassaemia) – Benefit assessment according to §35a Social Code Book V]
2023	WorkSafeBC	Firefighting and polycythemia vera
2023	National Institute for Health and Care Excellence (NICE)	Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptoms. NICE technology appraisal guidance 934
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Trastuzumab deruxtecan (breast cancer, HER2+, at least 2 prior therapies) - Addendum to Commission A22-81]
2023	Health Sciences Institute in Aragon (IACS)	[Effectiveness, safety and efficiency of subconjunctival drainage devices using an ab-internal approach for primary open-angle glaucoma surgery]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Luspatercept (myelodysplastic syndrome) – Benefit assessment according to §35a Social Code Book V]
2023	WorkSafeBC	Efficacy of eye movement desensitization and reprocessing (EMDR) as treatment for major depression
2023	Agency for Care Effectiveness (ACE)	Cytosponge for the detection of patients with Barrett oesophagus
2023	National Institute for Health and Care Excellence (NICE)	Secukinumab for treating moderate to severe hidradenitis suppurativa. NICE technology appraisal guidance 935
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Loncastuximab tesirine (DLBCL and HGBL) - Benefit assessment according to § 35a Social Code Book V]
2023	WorkSafeBC	Low intensity pulsed ultrasound (LIPUS) for preventing fractures
2023	Agency for Care Effectiveness (ACE)	Zio XT for ambulatory ECG monitoring for patients suspected to have cardiac arrhythmia
2023	National Institute for Health and Care Excellence (NICE)	Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal). NICE technology appraisal guidance 936
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Asciminib (chronic myeloid leukaemia, Ph+, after ≥ 2 prior therapies)]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lutetium vipivotide tetraxetan (prostate cancer) – Addendum to Commission A23-01]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Loncastuximab tesirine (DLBCL and HGBL) – Addendum to Commission A23-45]
2023	Agency for Care Effectiveness (ACE)	MagTrace and SentiMag for locating sentinel lymph node in patients with breast cancer
2023	Health Technology Wales (HTW)	Robot-assisted thoracic surgery
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Brexucabtagene Autoleucel (new therapeutic indication: relapsed or refractory B-cell precursor acute lymphoblastic leukaemia, 26 years of age and above)]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Olaparib (prostate cancer) – Addendum to Commission A23-03]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tisagenlecleucel (diffuse large B-cell lymphoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)]
2023	Agency for Care Effectiveness (ACE)	Optune for the treatment of newly diagnosed and recurrent glioblastoma
2023	Ontario Health	Supplemental Screening as an Adjunct to Mammography for Breast Cancer Screening in People With Dense Breasts
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Valoctocogene roxaparvovec (severe haemophilia A)]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Trastuzumab deruxtecan (breast cancer) – Addendum to Commission A23-07]
2023	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Cost-utility analysis of universal neonatal screening for critical congenital heart disease based on pulsioximetry in Spain]
2023	Agency for Care Effectiveness (ACE)	The CADScor System as a rule-out test for symptomatic patients suspected to have coronary artery disease
2023	Center for Drug Evaluation (CDE)	[Evaluation of the effectiveness of long-acting antipsychotic injections and future recommendations for mental health care in Taiwan's National Health Insurance System]
2023	Canary Health Service	[Software to support decisions for the administration of medicines in neonatal and paediatric intensive care units]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Sotorasib (NSCLC) – Addendum to Commission A23-06]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guides and standards: urinary tract infection in people aged 14 and over - diagnostic guidelines, optimal use of 1st- and 2nd-line treatments and follow-up ]
2023	Agency for Care Effectiveness (ACE)	Paige Prostate Detect to assist the diagnosis of prostate cancer
2023	Center for Drug Evaluation (CDE)	[Analysis of the effectiveness of various hemophilia treatments in Taiwan]
2023	Canary Health Service	[Transcranial direct current stimulation device for the treatment of drug-resistant epilepsy]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Vutrisiran (hereditary transthyretin amyloidosis) - Benefit assessment according to § 35a SGB V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ibrutinib (previously untreated chronic lymphocytic leukaemia) – Addendum to Commission A23-04]
2023	Health Information and Quality Authority (HIQA)	Ultra-hypofractionated adjuvant radiotherapy for breast cancer: evidence synthesis to support a generic justification decision
2023	Agency for Care Effectiveness (ACE)	HeartFlow FFRCT for the diagnosis of coronary artery disease
2023	Center for Drug Evaluation (CDE)	[Review of domestic and international drug addiction replacement treatment policies and cost-effectiveness analysis of methadone treatment in Taiwan]
2023	Canary Health Service	[Targeted muscle reinnervation in individuals with amputated limbs]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: barriers and facilitators encountered by women living with a physical disability (PD), intellectual disability (ID) or autism spectrum disorder (ASD) when using perinatal services]
2023	Scottish Health Technologies Group (SHTG)	Technology enabled theatre scheduling tools
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Finerenone (CKD stage 1 and 2) – Addendum to Commission A23-14]
2023	Health Information and Quality Authority (HIQA)	An overview of national approaches to stockpiling of medical countermeasures for public health emergencies
2023	Agency for Care Effectiveness (ACE)	Rapid to aid the diagnosis of patients suspected of stroke
2023	Center for Drug Evaluation (CDE)	[Evaluation of the optimal fixed subsidies strategy for pneumococcal vaccination in the elderly]
2023	Canary Health Service	[Genicular artery embolization for the treatment of knee osteoarthritis]
2023	Health Technology Wales (HTW)	Multi-grip myoelectric upper-limb prosthetics
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Finerenone (CKD stage 3 and 4) – Addendum to Commission A23-15]
2023	Health Information and Quality Authority (HIQA)	Health technology assessment of the addition of spinal muscular atrophy (SMA) to the National Newborn Bloodspot Screening Programme
2023	Agency for Care Effectiveness (ACE)	AcQMap for patients with cardiac arrhythmia
2023	Canary Health Service	[Intraoperative radiotherapy in resectable brain tumors and metastases]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guides and standards: acute exacerbation of chronic obstructive pulmonary disease -diagnostic approach, optimal use of treatments, and follow-up]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Dapagliflozin (heart failure with LVEF > 40 %) – Addendum to Commission A23-11]
2023	NIHR Health Technology Assessment programme	Implementing early rehabilitation and mobilisation for children in UK paediatric intensive care units: the PERMIT feasibility study
2023	Agency for Care Effectiveness (ACE)	KardiaMobile for the detection of atrial fibrillation
2023	Center for Drug Evaluation (CDE)	[Assessment of the optimal implementation strategy for pneumococcal vaccination policies in groups at high risk of invasive pneumococcal disease]
2023	Canary Health Service	[Clinical effectiveness and cost-effectiveness of the extension of colorectal cancer screening up to 74 years of age in general population]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: Zemaira - congenital alpha1- antitrypsin deficiency]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Belantamab mafodotin (multiple myeloma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Penile traction therapy for induratio penis plastica]
2023	Health Sciences Institute in Aragon (IACS)	[Molecular study of common apoE gene polymorphisms associated with familial dysbetalipoproteinaemia and late-onset Alzheimer’s disease]
2023	Canary Health Service	[Effectiveness, safety and cost-effectiveness of real time continuous glucose monitoring systems, open-loop systems and hybrid closed-loop systems (artificial pancreas) for patients with diabetes]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guides and standards: optimal use of echocardiography in Québec- diagnosis and follow-up of chronic heart failure]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: Glassia – congenital alpha1- antitrypsin deficiency]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Exagamglogene autotemcel (transfusion-dependent β-thalassaemia) - Assessment according to §35a Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Nivolumab (NSCLC, combination with platinum-based chemotherapy, neoadjuvant) – Benefit assessment according to §35a Social Code Book V]
2023	Canary Health Service	[Melanoma detection without biopsy using a non-invasive adhesive patch]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: Prolastin-C Liquid – congenital alpha1-antitrypsin deficiency]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tabelecleucel (relapsed or refractory Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), pretreated, 2 years and older) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Mavacamten (cardiomyopathy) – Benefit assessment according to §35a Social Code Book V]
2023	Canary Health Service	[Cost-effectiveness of systematic vaccination against invasive meningococcal disease due to serogroup B in childhood]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: relevant practices for promoting hearing health in long-term residential care settings]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Etranacogene dezaparvovec (haemophilia B) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Eftrenonacog alfa (haemophilia B) – Benefit assessment according to §35a Social Code Book V]
2023	Canary Health Service	[Neuropsychological rehabilitation in people with paediatric cancer]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Setmelanotide (Bardet Biedl syndrome) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2023	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Empagliflozin (renal insufficiency) - Benefit assessment according to § 35a Social Code Book V]
2023	Canary Health Service	[Determination by chemiluminescence of autoantibodies to domain 1 of beta 2 glycoprotein I in patients with antiphospholipid syndrome]
2023	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of practice: developing portraits to support the ongoing adaptation of youth services by local service networks]